Abstract:The integrin αVβ3 receptor has been implicated in several important diseases, but no αVβ3 antagonists are approved for human therapy. One possible limitation of current small-molecule antagonists is their ability to induce a major conformational change in the receptor that induces it to adopt a high-affinity ligand-binding state. In response, we used structural inferences from a pure peptide antagonist to design the small-molecule pure antagonists TDI-4161 and TDI-3761. Both compounds inhibit αVβ3-mediated cell adhesion to αVβ3 ligands, but do not induce the conformational change as judged by antibody binding, electron microscopy, X-ray crystallography, and receptor priming studies. Both compounds demonstrated the favorable property of inhibiting bone resorption in vitro , supporting potential value in treating osteoporosis. Neither, however, had the unfavorable property of the αVβ3 antagonist cilengitide of paradoxically enhancing aortic sprout angiogenesis at concentrations below its IC50, which correlates with cilengitide’s enhancement of tumor growth in vivo . Significance Statement αVβ3 is a potential therapeutic target for several important human diseases, but there are currently no αVβ3 antagonists approved for human therapy. Current candidates are primarily based on the Arg-Gly-Asp (RGD) motif and act as partial agonists in that they induce αVβ3 to undergo a conformational change that converts it into a high-affinity ligand-binding state. We have used structure-guided design to produce pure small-molecule αVβ3 antagonists that do not induce the conformational change as judged by protein crystallography, electron microscopy, and receptor priming. These compounds inhibit αVβ3-mediated bone resorption in vitro , but unlike the partial agonist cilengitide, do not enhance angiogenesis at low doses, a property that correlates with low-dose cilengitide’s enhancement of tumor growth in vivo . These pure αVβ3 antagonists can help define αVβ3’s role in animal models. If they demonstrate benefits over partial agonists in these model systems, they may be appropriate to consider for human therapy.

Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α v β 6 Integrin Inhibitors

Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic αvβ6 Integrin Inhibitors

Core Modifications of GSK3335103 toward Orally Bioavailable α v β 6 Inhibitors with Improved Synthetic Tractability

Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability

The Discovery of MORF-627, a Highly Selective Conformationally-Biased Zwitterionic Integrin αvβ6 Inhibitor for Fibrosis

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

Arylamide Derivatives As Allosteric Inhibitors Of The Integrin Alpha(2)Beta(1)/Type I Collagen Interaction

Arylamide derivatives as allosteric inhibitors of the integrin α2β1/type I collagen interaction

Chemical Modifications on the αvβ6 Intergrin Targeting A20FMDV2 Peptide: A review.

Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

Discovery of a potent, Highly selective, and In vivo anti-inflammatory Efficacious, P2Y 6 R antagonist with a novel quinoline-pyrazole scaffold

Unraveling the molecular basis for effective regulation of integrin α5β1 for enhanced therapeutic interventions

Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone Derivatives

Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities

Binding Investigation of Integrin Αvβ3 with Its Inhibitors by SPR Technology and Molecular Docking Simulation

Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases

Novel Pure Αvβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations